Biological systems regulate themselves through activation and inactivation cycles, the balance of which is crucial in allowing or suppressing signaling cascades and their downstream effects. Phosphorylation (activation) and dephosphorylation (inactivation) processes govern kinase signaling pathways. Because kinase pathway hyperactivity is a causal and crucial factor in the development of cardiac diseases, the creation of pharmacological inhibitors has been a hot topic of research. Enhancing the activity of inhibited but possibly helpful kinase activities, on the other hand, offers another therapeutic option. Kinase dephosphorylation by phosphatases results in route inactivation and suppression in this circumstance. Inhibiting the inhibitors thus gives a mechanism to boost the activity of specific pathways.
